Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life

Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life

Ilaria Cuomo,1,2 Georgios D Kotzalidis,1 Simone de Persis,2 Daria Piacentino,1 Filippo Perrini,2 Emanuela Amici,2 Sergio De Filippis1,2 1Department of Neurosciences, Mental Health, and Sensory Organs (NESMOS), Sapienza School of Medicine and Psychology, Sant’Andrea Hospital, Rome, Italy;...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Cuomo I, Kotzalidis GD, de Persis S, Piacentino D, Perrini F, Amici E, De Filippis S
Format: article
Langue:EN
Publié: Dove Medical Press 2018
Sujets:
Psychosis
Schizophrenia spectrum and other psychotic disorders
Bipolar disorder
Long-acting injectable antipsychotic drugs
Aripiprazole once-monthly
Paliperidone once-monthly
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Accès en ligne:https://doaj.org/article/bd4b5f7866b44701a1fdba29672c6bc3
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
Soyez le premier à ajouter un commentaire!
Il faut se connecter d'abord

Documents similaires